Emerging Infectious Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Laboratory Testing and Point of care testing), By Technology (Polymerase chain reaction, Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), and Others), By Type of Infection (Bacterial, Viral, Fungal, and Others), By Disease Type (Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), and Others), By End user (Hospitals & Clinics, Diagnostic laboratories, and Others), By Region and Competition, 2019-2029F

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 15.24 Billion

Market Size (2029)

USD 24.83 Billion

CAGR (2024-2029)

8.55%

Fastest Growing Segment

Laboratory Testing

Largest Market

North America

Market Overview

Global Emerging Infectious Disease Diagnostics Market was valued at USD 15.24 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.55% through 2029. The Global Emerging Infectious Disease Diagnostics Market represents a sector dedicated to the development, production, and distribution of diagnostic tools and tests designed to detect novel and re-emerging infectious diseases. This market has gained immense significance due to the increasing occurrence of epidemics and pandemics, such as COVID-19, which require rapid and accurate diagnostics to effectively manage and contain outbreaks. The field is characterized by innovations in technology, such as molecular diagnostics and point-of-care testing devices, which are vital in enhancing the speed and efficiency of disease detection and response strategies around the world.

Key Market Drivers

Increasing Prevalence of Infectious Diseases

The increasing prevalence of infectious diseases is a key driving force behind the growth and expansion of the global Emerging Infectious Disease Diagnostics Market. Infectious diseases are caused by pathogens such as bacteria, viruses, fungi, and parasites, and they can be transmitted from person to person or through vectors like mosquitoes or contaminated food and water. According to World Health Organization (WHO) statistics, vector-borne diseases account for over 700 000 deaths and more than 17 % of all infections in the world every year. Anopheline mosquito-transmitted malaria is responsible for over 400 000 deaths and about 219 million cases worldwide every year. The dengue is responsible for more than 96 million symptom cases and about 40 000 deaths every year which has raised significant concerns about global health security and the need for effective diagnostic solutions.

The emergence of novel infectious diseases, such as COVID-19, Ebola, Zika, and others, has highlighted the importance of early detection and rapid response to contain outbreaks. These diseases can spread rapidly and have the potential to cause significant morbidity and mortality, leading to a growing demand for accurate and timely diagnostic tests to identify and manage them effectively. There are many other factors contributing to the increasing prevalence of infectious diseases including globalization, urbanization, climate change, and changes in human behavior. Globalization has made it easier for infectious agents to spread from country to country through travel and trade. This makes it possible for pathogens to enter new countries and infect new people. Urbanization has increased the number of people living in cities, which creates an environment conducive to the transmission of infections. Climate change has changed the vectors’ distribution and behavior, which has had an impact on vector-borne diseases such as malaria, dengue, etc. Changes in human behavior, such as deforestation and the consumption of wildlife, can increase the likelihood of zoonotic diseases jumping from animals to humans.

As a result of these factors, the burden of infectious diseases continues to rise, driving the demand for diagnostic solutions that can quickly and accurately identify these diseases. The global Emerging Infectious Disease Diagnostics Market encompasses a wide range of diagnostic technologies, including molecular diagnostics, serological tests, point-of-care testing, and advanced imaging techniques. Governments, healthcare organizations, and research institutions are actively investing in the development and implementation of these diagnostic tools to strengthen disease surveillance, improve outbreak preparedness, and enhance public health responses therefore, the increasing prevalence of infectious diseases presents significant challenges to global health and underscores the importance of robust and efficient diagnostic solutions. The global Emerging Infectious Disease Diagnostics Market is propelled by the urgent need to detect and manage these diseases effectively, and ongoing advancements in diagnostic technologies will play a crucial role in curbing the impact of infectious diseases and safeguarding public health worldwide.

Increase In Funding from Private & Government Organizations

Government support and funding play an important role in expanding the market for diagnostics for infectious diseases. Governments can fund research and development of diagnostic technologies and implement targeted programs to develop new and effective diagnostic tools. In 2020, the Government of India announced the setting up of three new high throughput Indian Council of Medical Research (ICMR) laboratories in Kolkata, Mumbai, and Noida to increase the COVID-19 test capacity. In addition to COVID-19, these labs are used for other diagnosis tests for infectious diseases like HIV, hepatitis, tuberculosis, and dengue. Rising awareness of early diagnosis and treatment of infectious diseases and growing number of IT systems to develop advanced diagnostic equipment are expected to provide lucrative opportunities for expanding the global infectious disease diagnostics market in the coming years. Pneumococcal pneumonia is diagnosed in approximately 300,000 people aged 50 and over in the United States each year, according to a report published by the U.S. Food and Drug Administration (FDA) in 2020.

Government-sponsored grants and incentives also increase the cost and availability of diagnostics, allowing vulnerable populations to receive timely and high-quality diagnostics. Government-sponsored public health monitoring and control programs necessitate large-scale testing, increasing the need for diagnostics. Regulatory support from government agencies expedites the approval process for new diagnostic products, facilitating their entry into the market. Government initiatives focusing on epidemic preparedness and response boost the demand for diagnostics during outbreaks. Public awareness campaigns further stimulate the demand as they educate the population about the importance of early diagnosis. Overall, government initiatives and funding act as catalysts, promoting growth in the infectious disease diagnostics market and improving overall healthcare outcomes.

Technology Advancement in The Field of Infectious Disease Diagnostics

Innovations in molecular biology and genomics, as well as automation, have had a major influence on the emerging diagnostic market for infectious diseases. Diagnostic methods have evolved to detect infectious agents more quickly and accurately. With the advent of next-generation sequencing (NGS), imaging technologies, and point of care (POC) diagnostic equipment, diagnostics have become faster and more sensitive, allowing for earlier detection of emerging pathogens. Telemedicine and digital health platforms have enhanced remote diagnosis and data sharing, enabling real-time surveillance and response to outbreaks. These innovations attract increased investment from both public and private sectors, leading to the development of cutting-edge diagnostic solutions. As technology continues to evolve, it is likely to further drive the market by expanding capabilities, improving cost-effectiveness, and ultimately aiding in the control and containment of emerging infectious diseases. Neuberg Diagnostic is a leading provider of top-of-the-line laboratories. In May 2021, the clinical laboratory opened its doors in the United States to provide genomic and molecular testing based on next generation sequencing technology.

Expansion of Point-Of-Care Diagnostic Platforms

The expansion of point-of-care (POC) diagnostic platforms is significantly increasing the demand for emerging infectious disease diagnostics globally. These POC platforms offer rapid and convenient testing capabilities outside of traditional laboratory settings, enabling timely diagnosis and management of infectious diseases at the point of patient care. As emerging infectious diseases continue to pose significant public health threats, the need for rapid and accurate diagnostics is paramount for effective outbreak control and containment. POC diagnostic platforms empower healthcare providers to quickly identify infectious pathogens, initiate appropriate treatments, and implement infection control measures, thereby reducing transmission rates and mitigating the spread of disease. The growing availability and adoption of POC diagnostic platforms are driving demand for emerging infectious disease diagnostics, stimulating innovation in diagnostic technologies and expanding access to diagnostic testing in diverse healthcare settings globally.


Download Free Sample Report

Key Market Challenges

Limited Access to Diagnostic Tools

Limited access to diagnostic tools is a significant factor decreasing the demand for emerging infectious disease diagnostics globally. In many regions, particularly in low- and middle-income countries, healthcare systems face challenges in accessing and implementing advanced diagnostic technologies due to factors such as limited infrastructure, inadequate funding, and workforce shortages. As a result, healthcare providers often rely on conventional diagnostic methods that may lack sensitivity, specificity, and timeliness in detecting emerging infectious diseases. Limited access to diagnostic tools hampers the ability to promptly diagnose and respond to outbreaks, leading to delays in containment efforts and exacerbating the spread of infectious pathogens. The high cost of acquiring and maintaining advanced diagnostic equipment poses a barrier to adoption, particularly in resource-constrained settings. Addressing these challenges requires concerted efforts to improve access to affordable and portable diagnostic tools, strengthen laboratory capacity, and enhance training programs for healthcare personnel. By overcoming barriers to access, the demand for emerging infectious disease diagnostics can be bolstered, facilitating more effective disease surveillance, outbreak response, and public health interventions globally.

Genetic Mutation of Pathogens

The genetic mutation of pathogens presents a challenge that decreases the demand for emerging infectious disease diagnostics globally. Pathogens, especially viruses and bacteria, have the capacity to mutate rapidly, leading to the emergence of new strains or variants with altered characteristics. These genetic mutations can affect the accuracy and reliability of diagnostic tests designed to detect specific pathogens, as the genetic changes may impact the binding affinity of diagnostic reagents or alter the target sequences recognized by molecular assays. Consequently, existing diagnostic tools may become less effective in identifying newly evolved strains, resulting in decreased demand for these diagnostics. The complexity of genetic mutations can complicate the development and validation of new diagnostic assays tailored to emerging pathogen variants, further dampening demand. Addressing the challenge of genetic mutation requires ongoing surveillance efforts, continuous refinement of diagnostic technologies, and agile response strategies to adapt to evolving pathogens, thereby ensuring the effectiveness of emerging infectious disease diagnostics in a dynamic global health landscape.

Key Market Trends

Integration of Artificial Intelligence in Diagnostics

The integration of artificial intelligence (AI) in diagnostics is significantly increasing the demand for emerging infectious disease diagnostics globally. AI-powered diagnostic systems leverage advanced algorithms and machine learning techniques to analyze complex datasets, identify patterns, and generate accurate diagnostic results with unprecedented speed and accuracy. In the context of emerging infectious diseases, where timely detection and rapid response are critical, AI-enabled diagnostics offer invaluable capabilities for early detection, outbreak surveillance, and predictive modeling. These AI-driven solutions enable healthcare providers to quickly identify novel pathogens, track disease transmission dynamics, and inform public health interventions, thereby enhancing preparedness and response efforts. As the global burden of emerging infectious diseases continues to rise, fueled by factors such as urbanization, globalization, and climate change, the demand for AI-driven diagnostic solutions is surging. Consequently, there is growing investment in AI-based diagnostic technologies and increased adoption of these innovative tools in healthcare systems worldwide, driving market growth and fostering innovation in emerging infectious disease diagnostics.

Escalating Number of Hospital-Acquired Infections

The escalating number of hospital-acquired infections is significantly increasing the demand for emerging infectious disease diagnostics globally. Hospital-acquired infections (HAIs) pose a significant threat to patient safety, leading to increased morbidity, mortality, and healthcare costs. With the emergence of multidrug-resistant pathogens and the persistence of healthcare-associated outbreaks, there is a growing urgency to implement robust diagnostic strategies for early detection and effective management of these infections. Emerging infectious disease diagnostics play a crucial role in identifying and controlling HAIs by enabling healthcare providers to quickly identify the causative pathogens, determine antimicrobial susceptibilities, and implement targeted infection control measures. As healthcare facilities strive to enhance infection prevention and control practices to mitigate the risk of HAIs, there is a heightened demand for advanced diagnostic technologies capable of rapidly and accurately detecting both known and novel pathogens associated with hospital-acquired infections. Consequently, the escalating number of HAIs is driving the adoption of emerging infectious disease diagnostics globally, underscoring the critical role of diagnostic innovation in safeguarding patient health and improving healthcare outcomes.

Segmental Insights

Application Insights

Based on the Application, Laboratory Testing has traditionally dominated the market due to its high level of accuracy, ability to handle large test volumes, and the availability of advanced testing capabilities. However, in recent times, Point of Care Testing (POCT) has gained significant traction because of its rapid diagnostic capabilities, convenience, and the crucial role it plays in quick decision-making at the patient's side.

With Point of Care Testing, healthcare providers can obtain rapid results directly at the point of patient care, allowing for immediate treatment decisions and reducing the time between testing and diagnosis. This is particularly beneficial in emergency situations or in resource-limited settings where time is of the essence. Despite the surge in POCT's popularity, Laboratory Testing continues to hold a substantial market share. This is partly due to technological advancements that have improved the speed and efficiency of laboratory tests, as well as the complex nature of certain tests that necessitate sophisticated lab equipment and expertise. Laboratory testing provides a comprehensive analysis of samples, allowing for a more detailed assessment of a patient's condition.

End User Insights

Based on the end-user segment, the global Emerging Infectious Disease Diagnostics Market is currently dominated by hospitals and clinics, which serve as critical hubs for infectious disease detection and treatment. These healthcare facilities play a pivotal role in providing comprehensive resources for rapid testing, accurate diagnosis, and optimal patient care. With a high volume of patient traffic, hospitals and clinics are equipped to handle the immediate need for infection control measures, ensuring the safety and well-being of both patients and healthcare professionals. This dedication to quality care and the ability to adapt to evolving infectious disease challenges contribute significantly to the leading position of hospitals and clinics in the market.


Download Free Sample Report

Regional Insights

The North American region currently dominates the Emerging Infectious Disease Diagnostics Market. This dominance is attributed to several factors, including an advanced healthcare infrastructure that enables efficient diagnosis and treatment of infectious diseases. The region's high healthcare expenditure signifies the commitment towards ensuring the well-being of its population. North America has a strong presence of leading diagnostic companies that constantly innovate and develop cutting-edge diagnostic solutions. This, coupled with the increased incidence of infectious diseases, creates a conducive environment for the growth of the diagnostics market in the region.

The swift adoption of advanced technologies in diagnostics, such as molecular diagnostics and point-of-care testing, plays a crucial role in sustaining North America's market leadership. These technologies allow for rapid and accurate detection of infectious diseases, enabling timely intervention and effective disease management. Overall, the combination of advanced healthcare infrastructure, high healthcare expenditure, presence of leading diagnostic companies, increased incidence of infectious diseases, and the adoption of advanced technologies positions North America at the forefront of the Emerging Infectious Disease Diagnostics Market.

Recent Developments

  • In June 2023, T2 Biosystems announced a clinical collaboration with Vanderbilt University Medical Center to implement and evaluate the T2 bacteria panel for clinical use.
  • In July 2023, the FDA granted Breakthrough Device status to T2 Biosystems’ direct-from-blood molecular diagnostic test for Candida auris (C. auris). This designation represents the third product from T2 Biosystems to receive such recognition, following the FDA's previous grants for its T2Resistance Panel and T2Lyme Panel. T2 Biosystems aims to enhance its FDA-cleared T2Dx Instrument's test offerings by integrating the C. auris diagnostic test. This test is engineered to swiftly identify C. auris species in blood samples within three to five hours, eliminating the need for extended waiting periods associated with traditional blood cultures.
  • In April 2023, DYNEX Technologies and Tecan unveiled a partnership aimed at enhancing the accessibility of top-notch ELISA products across the United States. Alongside DYNEX's range of fully automated ELISA workstations, customers will now gain access to Tecan's comprehensive assortment of ELISA-focused kits and reagents. Through this collaboration, both companies are poised to extend their presence and cater to a broader customer base within the U.S. market.
  • QIAGEN N.V. introduced new syndromic testing solutions in Japan In April 2023.
  • In February 2023, Thermo Fisher Scientific Inc. and Mylab announced a collaboration to develop test kits for infectious diseases.
  • In February 2023 Sherlock Biosciences acquired Sense Biodetection, a molecular diagnostic company, to accelerate the commercialization of its CRISPR-based diagnostic test.

Key Market Players

  • BioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Becton Dickinson & Company
  • Agilent Technologies, Inc.
  • Abbott Laboratories Inc
  • Thermo Fisher Scientific Inc
  • Roche Diagnostics Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • Danaher Corporation

By Application

By Technology

By Type of Infection

By Disease Type

By End User

By Region
  • Laboratory Testing
  • Point of Care Testing
  • Polymerase Chain Reaction
  • Immunodiagnostics
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Next-Generation Sequencing (NGS)
  • Others
  • Bacterial
  • Viral
  • Fungal
  • Others
  • Respiratory Infections
  • Gastrointestinal Infections
  • Sexually Transmitted Infections (STIs)
  • Others
  • Hospitals & Clinics
  • Diagnostic laboratories
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

 

Report Scope:

In this report, the Global Emerging Infectious Disease Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Emerging Infectious Disease Diagnostics Market, By Application:

o   Laboratory Testing

o   Point of Care Testing

  • Emerging Infectious Disease Diagnostics Market, By Technology:

o   Polymerase Chain Reaction

o   Immunodiagnostics

o   Isothermal Nucleic Acid Amplification Technology (INAAT)

o   Next-Generation Sequencing (NGS)

o   Others

  • Emerging Infectious Disease Diagnostics Market, By Type of Infection:

o   Bacterial

o   Viral

o   Fungal

o   Others

  • Emerging Infectious Disease Diagnostics Market, By Disease Type:

o   Respiratory Infections

o   Gastrointestinal Infections

o   Sexually Transmitted Infections (STIs)

o   Others

  • Emerging Infectious Disease Diagnostics Market, By End User:

o   Hospitals & Clinics

o   Diagnostic laboratories

o   Others

  • Emerging Infectious Disease Diagnostics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Emerging Infectious Disease Diagnostics Market.

Available Customizations:

Global Emerging Infectious Disease Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Emerging Infectious Disease Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the study

2.2.  Baseline methodology

2.3.  Key industry partners

2.4.  Major association and secondary sources

2.5.  Forecasting methodology

2.6.  Data triangulation & validation

2.7.  Assumptions and limitations

3.    Impact Of Covid-19 On Global Emerging Infectious Disease Diagnostics Market

4.    Executive Summary

4.1.  Overview of the market

4.2.  Overview of key market segmentations

4.3.  Overview of key market players

4.4.  Overview of key regions/countries

4.5.  Overview of market drivers, challenges, trends

5.    Voice of Customer

6.    Global Emerging Infectious Disease Diagnostics Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Application (Laboratory Testing and Point of Care Testing)

6.2.2.    By Technology (Polymerase Chain Reaction, Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), And Others)

6.2.3.    By Type of Infection (Bacterial, Viral, Fungal, and Others)

6.2.4.    By Disease Type (Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), and Others)

6.2.5.    By End User (Hospitals & Clinics, Diagnostic laboratories, and Others)

6.2.6.    By Region

6.2.7.    By Company (2023)

6.3.  Market Map

7.    North America Emerging Infectious Disease Diagnostics Market Outlook

7.1.  Market Size & Forecast       

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Application

7.2.2.    By Technology

7.2.3.    By Type of Infection

7.2.4.    By Disease Type

7.2.5.    By End user

7.2.6.    By Country

7.3.  North America: Country Analysis

7.3.1.    United States Emerging Infectious Disease Diagnostics Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Application

7.3.1.2.2.           By Technology

7.3.1.2.3.           By Type of Infection

7.3.1.2.4.           By Disease type

7.3.1.2.5.           By End user

7.3.2.    Canada Emerging Infectious Disease Diagnostics Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Application

7.3.2.2.2.           By Technology

7.3.2.2.3.           By Type of Infection

7.3.2.2.4.           By Disease type

7.3.2.2.5.           By End user

7.3.3.    Mexico Emerging Infectious Disease Diagnostics Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Application

7.3.3.2.2.           By Technology

7.3.3.2.3.           By Type of Infection

7.3.3.2.4.           By Disease type

7.3.3.2.5.           By End user

8.    Europe Emerging Infectious Disease Diagnostics Outlook

8.1.  Market Size & Forecast       

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Application

8.2.2.    By Technology

8.2.3.    By Type of Infection

8.2.4.    By Disease Type

8.2.5.    By End user

8.2.6.    By Country

8.3.  Europe: Country Analysis

8.3.1.    Germany Emerging Infectious Disease Diagnostics Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Application

8.3.1.2.2.           By Technology

8.3.1.2.3.           By Type of Infection

8.3.1.2.4.           By Disease type

8.3.1.2.5.           By End user

8.3.2.    Italy Emerging Infectious Disease Diagnostics Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Application

8.3.2.2.2.           By Technology

8.3.2.2.3.           By Type of Infection

8.3.2.2.4.           By Disease type

8.3.2.2.5.           By End user

8.3.3.    France Emerging Infectious Disease Diagnostics Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Application

8.3.3.2.2.           By Technology

8.3.3.2.3.           By Type of Infection

8.3.3.2.4.           By Disease type

8.3.3.2.5.           By End user

8.3.4.    Spain Emerging Infectious Disease Diagnostics Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Application

8.3.4.2.2.           By Technology

8.3.4.2.3.           By Type of Infection

8.3.4.2.4.           By Disease type

8.3.4.2.5.           By End user

8.3.5.    United Kingdom Emerging Infectious Disease Diagnostics Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.           By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.           By Application

8.3.5.2.2.           By Technology

8.3.5.2.3.           By Type of Infection

8.3.5.2.4.           By Disease type

8.3.5.2.5.           By End user

9.    Asia-Pacific Emerging Infectious Disease Diagnostics Market Outlook

9.1.  Market Size & Forecast       

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Application

9.2.2.    By Technology

9.2.3.    By Type of Infection

9.2.4.    By Disease Type

9.2.5.    By End user

9.2.6.    By Country

9.3.  Asia Pacific: Country Analysis

9.3.1.    China Emerging Infectious Disease Diagnostics Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Application

9.3.1.2.2.           By Technology

9.3.1.2.3.           By Type of Infection

9.3.1.2.4.           By Disease type

9.3.1.2.5.           By End user

9.3.2.    Japan Emerging Infectious Disease Diagnostics Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Application

9.3.2.2.2.           By Technology

9.3.2.2.3.           By Type of Infection

9.3.2.2.4.           By Disease type

9.3.2.2.5.           By End user

9.3.3.    India Emerging Infectious Disease Diagnostics Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Application

9.3.3.2.2.           By Technology

9.3.3.2.3.           By Type of Infection

9.3.3.2.4.           By Disease type

9.3.3.2.5.           By End user

9.3.4.    Australia Emerging Infectious Disease Diagnostics Market Outlook

9.3.4.1.        Market Size & Forecast

9.3.4.1.1.           By Value

9.3.4.2.        Market Share & Forecast

9.3.4.2.1.           By Application

9.3.4.2.2.           By Technology

9.3.4.2.3.           By Type of Infection

9.3.4.2.4.           By Disease type

9.3.4.2.5.           By End user

9.3.5.    South Korea Emerging Infectious Disease Diagnostics Market Outlook

9.3.5.1.        Market Size & Forecast

9.3.5.1.1.           By Value

9.3.5.2.        Market Share & Forecast

9.3.5.2.1.           By Application

9.3.5.2.2.           By Technology

9.3.5.2.3.           By Type of Infection

9.3.5.2.4.           By Disease type

9.3.5.2.5.           By End user

10. Middle East and Africa Emerging Infectious Disease Diagnostics Market Outlook

10.1.             Market Size & Forecast        

10.1.1. By Value

10.2.             Market Share & Forecast

10.2.1. By Application

10.2.2. By Technology

10.2.3. By Type of Infection

10.2.4. By Disease Type

10.2.5. By End user

10.2.6. By Country

10.3.             Middle East and Africa: Country Analysis

10.3.1. UAE Emerging Infectious Disease Diagnostics Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Application

10.3.1.2.2.         By Technology

10.3.1.2.3.         By Type of Infection

10.3.1.2.4.         By Disease type

10.3.1.2.5.         By End user

10.3.2. Saudi Arabia Emerging Infectious Disease Diagnostics Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Application

10.3.2.2.2.         By Technology

10.3.2.2.3.         By Type of Infection

10.3.2.2.4.         By Disease type

10.3.2.2.5.         By End user

10.3.3. South Africa Emerging Infectious Disease Diagnostics Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Application

10.3.3.2.2.         By Technology

10.3.3.2.3.         By Type of Infection

10.3.3.2.4.         By Disease type

10.3.3.2.5.         By End user

11. South America Emerging Infectious Disease Diagnostics Market Outlook

11.1.             Market Size & Forecast        

11.1.1. By Value

11.2.             Market Share & Forecast

11.2.1. By Application

11.2.2. By Technology

11.2.3. By Type of Infection

11.2.4. By Disease Type

11.2.5. By End user

11.2.6. By Country

11.3.             South America: Country Analysis

11.3.1. Brazil Emerging Infectious Disease Diagnostics Market Outlook

11.3.1.1.     Market Size & Forecast

11.3.1.1.1.         By Value

11.3.1.2.     Market Share & Forecast

11.3.1.2.1.         By Application

11.3.1.2.2.         By Technology

11.3.1.2.3.         By Type of Infection

11.3.1.2.4.         By Disease type

11.3.1.2.5.         By End user

11.3.2. Argentina Emerging Infectious Disease Diagnostics Market Outlook

11.3.2.1.     Market Size & Forecast

11.3.2.1.1.         By Value

11.3.2.2.     Market Share & Forecast

11.3.2.2.1.         By Application

11.3.2.2.2.         By Technology

11.3.2.2.3.         By Type of Infection

11.3.2.2.4.         By Disease type

11.3.2.2.5.         By End user

11.3.3. Colombia Emerging Infectious Disease Diagnostics Market Outlook

11.3.3.1.     Market Size & Forecast

11.3.3.1.1.         By Value

11.3.3.2.     Market Share & Forecast

11.3.3.2.1.         By Application

11.3.3.2.2.         By Technology

11.3.3.2.3.         By Type of Infection

11.3.3.2.4.         By Disease type

11.3.3.2.5.         By End user

12. Market Dynamics

12.1.             Drivers

12.2.             Challenges

13. Market Trends & Developments

13.1.             Merger & Acquisition (If Any)

13.2.             Product Launches (If Any)

13.3.             Recent Developments

14. Global Emerging Infectious Disease Diagnostics Market: SWOT Analysis

15. Porter’s Five Forces Analysis

15.1.             Competition in the Industry

15.2.             Potential of New Entrants

15.3.             Power of Suppliers

15.4.             Power of Customers

15.5.             Threat of Substitute Products

16. Competitive Landscape

16.1.             BioMérieux SA

16.1.1. Business Overview

16.1.2. Company Snapshot

16.1.3. Products & Services

16.1.4. Financials (As Reported)

16.1.5. Recent Developments

16.1.6. Key Personnel Details

16.1.7. SWOT Analysis

16.2.            Bio-Rad Laboratories, Inc.

16.3.            Becton Dickinson & Company

16.4.            Agilent Technologies, Inc.

16.5.            Abbott Laboratories Inc

16.6.            Thermo Fisher Scientific Inc

16.7.            Roche Diagnostics Corporation

16.8.            DiaSorin SpA

16.9.            F. Hoffmann-La Roche AG

16.10.         Danaher Corporation

17. Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Emerging Infectious Disease Diagnostics Market was estimated to be USD 15.24 Billion in 2023.

down-arrow

Hospitals and clinics dominate the global Emerging Infectious Disease Diagnostics Market. These facilities play a crucial role in detecting and treating infectious diseases, offering rapid testing, diagnosis, and patient care. With high patient traffic and a focus on infection control, they hold a leading position in the market.

down-arrow

The North American region leads the Emerging Infectious Disease Diagnostics Market due to advanced healthcare infrastructure, high healthcare expenditure, presence of leading diagnostic companies, and increased incidence of infectious diseases. Swift adoption of advanced technologies in diagnostics further contributes to its market leadership.

down-arrow

Increasing prevalence of infectious diseases and expansion of point-of-care diagnostic platforms are the major drivers for the Global Emerging Infectious Disease Diagnostics Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Emerging Infectious Disease Diagnostics Market to Grow at 8.55% CAGR through 2029

Apr, 2024

Integration of artificial intelligence in diagnostics and escalating number of hospital-acquired infections is expected to drive the Global Emerging Infectious Disease Diagnostics Market growth in th

Why Choose Us